|
Summary |
|||
|
|
|||
|
|
· |
Group sales +7% CER on a reported basis and +2% CER pro-forma |
|
|
|
|
- |
Pharmaceuticals £3.5 billion, -6% (+2% pro-forma); Vaccines £0.8 billion, +11% (-5% pro-forma); Consumer Healthcare £1.5 billion, +51% (+6% pro-forma) |
|
|
|
- |
New Pharmaceutical and Vaccine sales of £446 million in Q2 |
|
|
|
|
|
|
|
· |
Q2 core EPS of 17.3p, flat in CER terms |
|
|
|
|
- |
EPS reflects dilution of Novartis transaction, ongoing pricing pressure partly offset by cost reductions |
|
|
|
- |
Integration of new Consumer and Vaccine businesses on track |
|
|
|
- |
On track to deliver targeted annual cost savings of £3 billion from all restructuring programmes |
|
|
|
|
|
|
|
· |
Total Q2 EPS of 3.1p and H1 EPS of 170.7p |
|
|
|
|
- |
Reflects phasing of pre-tax transaction gains and accelerated restructuring charges |
|
|
|
|
|
|
|
· |
2015 earnings guidance and 2016 outlook reiterated |
|
|
|
|
- |
Expect 2015 core EPS to decline at a high teen percentage rate (CER) |
|
|
|
- |
2016 core EPS percentage growth expected to reach double digits (CER) |
|
|
|
|
|
|
|
· |
Q2 dividend of 19p declared |
|
|
|
|
- |
Continued expectation for full year dividend of 80p |
|
|
|
|
|
|
|
· |
R&D innovation with significant potential to drive long-term Group performance |
|
|
|
|
- |
Progress of new respiratory portfolio continues with positive FDA AdCom recommendation for Nucala and regulatory filing for approval in Japan |
|
|
|
- |
Positive CHMP decision received for Mosquirix |
|
|
|
- |
Group has ~40 NMEs (drugs and vaccines) in Phase II/III clinical development, primarily focused on HIV, Oncology, Vaccines, Cardiovascular, Immuno-inflammation and Respiratory diseases |
|
|
|
- |
New data and prospects for advanced/early-stage pipeline to be reviewed at R&D event in November |
|
|
|||
